Key Points in Managing PLA2R-Associated Membranous Nephropathy.
作者信息
Ramachandran Raja, Jha Vivekanand, Bose Bhadran
机构信息
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
George Institute for Global Health, New Delhi, India.
出版信息
Kidney Int Rep. 2024 May 27;9(8):2320-2322. doi: 10.1016/j.ekir.2024.05.028. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
Key Points in Managing PLA2R-Associated Membranous Nephropathy.管理磷脂酶A2受体相关膜性肾病的要点
Kidney Int Rep. 2024 May 27;9(8):2320-2322. doi: 10.1016/j.ekir.2024.05.028. eCollection 2024 Aug.
2
Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes.他克莫司可预防TWEAK诱导的人足细胞培养物中PLA2R的表达。
J Clin Med. 2020 Jul 10;9(7):2178. doi: 10.3390/jcm9072178.
3
Clinical significance of Mtype phospholipase A2 receptor and thrombospondin Type 1 domaincontaining 7A in primary membranous nephropathy.M型磷脂酶A2受体和含血小板反应蛋白1结构域7A在原发性膜性肾病中的临床意义
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Jun 28;45(6):693-700. doi: 10.11817/j.issn.1672-7347.2020.190109.
4
Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study.特发性膜性肾病和非典型膜性肾病患者血清甘露糖结合凝集素、抗磷脂酶 A2 受体抗体与肾脏结局的相关性：一项单中心回顾性队列研究。
Ren Fail. 2022 Dec;44(1):428-433. doi: 10.1080/0886022X.2022.2048016.
5
Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.神经表皮生长因子样 1 蛋白（NELL-1）相关膜性肾病。
Kidney Int. 2020 Jan;97(1):163-174. doi: 10.1016/j.kint.2019.09.014. Epub 2019 Oct 7.
6
Distribution spectrum and clinical significance of glomerular exostosin (EXT1) deposits in PLA2R-positive membranous nephropathy.PLA2R 阳性膜性肾病中肾小球外显子素（EXT1）沉积的分布谱及临床意义。
J Nephrol. 2024 Jan;37(1):149-158. doi: 10.1007/s40620-023-01779-6. Epub 2023 Oct 26.
7
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.每月小剂量利妥昔单抗治疗原发性抗 PLA2R 阳性膜性肾病：一种个体化方法。
BMC Nephrol. 2023 May 26;24(1):146. doi: 10.1186/s12882-023-03206-1.
8
A Case of Pla2r and Exostosin 1 Positive Membranous Nephropathy - The Diagnostic and Therapeutic Dilemma.一例伴有血小板膜糖蛋白A2R及外生骨疣蛋白1阳性的膜性肾病——诊断与治疗困境
Cureus. 2023 Aug 17;15(8):e43619. doi: 10.7759/cureus.43619. eCollection 2023 Aug.
9
Neural Epidermal Growth Factor-Like 1 Protein-Positive Membranous Nephropathy in Chinese Patients.中国患者的神经表皮生长因子样 1 蛋白阳性膜性肾病。
Clin J Am Soc Nephrol. 2021 May 8;16(5):727-735. doi: 10.2215/CJN.11860720. Epub 2021 Apr 13.
10
Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy.原发性抗磷脂综合征伴抗磷脂酶 A2 受体抗体阳性的膜性肾病。
BMC Nephrol. 2020 May 24;21(1):196. doi: 10.1186/s12882-020-01856-z.
引用本文的文献
1
Low-dose cyclophosphamide combined with chinese herbal medicine Shuli Fenxiao formula for the treatment of intermediate-to-high risk primary membranous nephropathy.低剂量环磷酰胺联合中药疏利分消方治疗中高危原发性膜性肾病
Front Immunol. 2025 Apr 22;16:1543581. doi: 10.3389/fimmu.2025.1543581. eCollection 2025.
2
Pilot Trial of Hydroxychloroquine as Add-On Therapy in Patients With Membranous Nephropathy.羟氯喹作为膜性肾病患者附加治疗的初步试验
Kidney Int Rep. 2024 Sep 21;9(12):3446-3454. doi: 10.1016/j.ekir.2024.09.016. eCollection 2024 Dec.
本文引用的文献
1
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
2
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.STARMEN 试验表明，在原发性膜性肾病中，与他克莫司和利妥昔单抗序贯治疗相比，皮质类固醇和环磷酰胺交替治疗更具优势。
Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.
3
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.利妥昔单抗或环孢素治疗膜性肾病。
N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.
4
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.磷脂酶A2受体（PLA2R）抗体相关膜性肾病的免疫缓解：环磷酰胺与利妥昔单抗对比
Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019.
5
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.特发性膜性肾病 cyclophosphamide 治疗后的癌症风险。
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1066-73. doi: 10.2215/CJN.08880813. Epub 2014 May 22.
6
Venous thromboembolism in patients with membranous nephropathy.膜性肾病患者的静脉血栓栓塞症。
Clin J Am Soc Nephrol. 2012 Jan;7(1):43-51. doi: 10.2215/CJN.04250511. Epub 2011 Nov 10.
Zotero 插件